| abstract |
Compounds with an increased efficiency of modulating the activity of the NMDA receptor are described. These compounds are intended for use in the treatment of pathological conditions such as depression and related disorders. Orally accessible compositions and other pharmaceutically acceptable forms of delivery of the compounds, including intravenous compositions, are also described. |